Antleron

Explore new gene therapy innovations in the 𝟱-𝗱𝗮𝘆 𝘁𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗰𝗼𝘂𝗿𝘀𝗲 𝗼𝗻 ‘𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀: 𝗙𝗿𝗼𝗺 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝘁𝗼 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗕𝗲𝗻𝗲𝗳𝗶𝘁’, co-organized by EATRIS, KU Leuven and GET-IN DN MSCA.  This immersive workshop is for 𝗣𝗵𝗗 𝘀𝘁𝘂𝗱𝗲𝗻𝘁𝘀, 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗽𝗼𝘀𝘁𝗱𝗼𝗰𝘀 and 𝘆𝗼𝘂𝗻𝗴 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 eager to delve into the world of gene therapies. This course covers the 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲, 𝗳𝗿𝗼𝗺 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗽𝗿𝗶𝗻𝗰𝗶𝗽𝗹𝗲𝘀 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀. Two of our fellows will take the stage to deliver an insightful presentation: • “𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗯𝗮𝘀𝗶𝘀 𝗼𝗳 𝗔𝗧𝗠𝗣 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀” by Prof. Rik Gijsbers of KU Leuven • “𝗤𝗯𝗗 𝗮𝗻𝗱 𝗿𝗶𝘀𝗸 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁” by Jan Schrooten, CEO of Antleron  See comments for practical info and registration.  🗓 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟴-𝟮𝟯, 𝟮𝟬𝟮𝟰  📍 𝗞𝗨 𝗟𝗲𝘂𝘃𝗲𝗻 #BioProcesses #ATMP #PersonalizedTherapies #PersonalizedMedicine #CellTherapy #GeneTherapy Antleron 

Antleron fellows Evan Claes, Rik Gijsbers and Jan Schrooten will be attending the 𝗘𝗦𝗚𝗖𝗧 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗻 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 (CGT) development in Rome. They will present two posters to an international audience, showcasing specific CGT innovations: • 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝗳𝗶𝘅𝗲𝗱-𝗯𝗲𝗱 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 enabling sustainable process development of HEK293-based viral vector upstream biomanufacturing  • 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝗮𝗻𝗱 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗰𝗲𝗹𝗹 & 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 via multi-objective optimization Our specialists develop 𝗰𝘂𝘀𝘁𝗼𝗺 𝗖𝗚𝗧 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 𝗮𝗻𝗱 𝗳𝗮𝘀𝘁-𝘁𝗿𝗮𝗰𝗸 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 toward pre-defined objectives by using 𝗔𝗻𝘁𝗹𝗲𝗿𝗼𝗻’𝘀 𝗽𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗯𝗶𝗼𝗿𝗲𝗮𝗰𝘁𝗼𝗿 𝗮𝗻𝗱 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀. These Antleron innovations enable CGT to become a sustainable health solution by improving CGT quality, scalability, accessibility and affordability. Feel free to send a message to Evan, Rik, or Jan to arrange a meeting to discuss your CGT development plans and challenges. We partner with Novasign and the Leuven Viral Vector Core on digital twins and smart bioprocesses, respectively. #CGT #CellTherapy #GeneTherapy #ESGCT2024 #LeuvenViralVectorCore Novasign Antleron

Our Antleron Fellows, Jan Schrooten 𝗮𝗻𝗱 Filip Donvil, 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗕𝗲𝗹𝗴𝗶𝘂𝗺 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in Namur on October 15. At the event, CEO Jan Schrooten will be presenting 𝗔𝗻𝘁𝗹𝗲𝗿𝗼𝗻’𝘀 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝘀𝗺𝗮𝗿𝘁 𝗯𝗶𝗼𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, so don’t miss the pitching sessions! We look forward to connecting with you at this event for innovators from both the Flemish and Walloon regions. Feel free to send Jan or Filip a message to schedule a 𝗼𝗻𝗲-𝗼𝗻-𝗼𝗻𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗱𝗶𝘀𝗰𝘂𝘀𝘀 𝘆𝗼𝘂𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗹𝗮𝗻𝘀 𝗮𝗻𝗱 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀.  Antleron’s multidisciplinary team creates biomanufacturing solutions and infrastructure platforms to 𝗯𝗿𝗶𝗻𝗴 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 (𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱) 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗳𝗮𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝗰𝗹𝗼𝘀𝗲𝗿 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗶𝗻 𝗮 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝘄𝗮𝘆. #PersonalizedTherapies #atmp #BioManufacturing Advanced Therapies in Belgium Antleron MEDVIA BioWin

Watch Katerina Leonida explain the PhD project she embarked on with GET-IN and partner Antleron. Katerina is a Greek chemical engineer who is developing a detailed digital twin of upstream unit operations for AAV-based gene therapy manufacturing.    Katerina Leonida: “The digital twin will enable model-based optimization of novel manufacturing processes, making them more practical, straightforward, and cost-effective to scale reliably and economically.”    Full story 👉 https://lnkd.in/ewNq74wC    #DigitalTwin #GeneTherapy #AAV GET-IN DN MSCA Antleron  

The day after tomorrow, September 12, our colleagues Anaïs Schaschkow and Pascale BERTHET will attend the Annual Meeting of BESEV 2024 in Liège, Belgium. The scientific poster they will present highlights Antleron's smart bioprocess platform as part of a co-development project with ConvEyXO. This innovative platform enhances the availability, accessibility, and affordability (3A) of Extracellular Vesicles (EVs). The platform supports economical and sustainable EV production, essential for ensuring the 3As of future EV-based therapies for patients. #bioprocesses #ExtracellularVesicles #BESEV Belgian Society for Extracellular Vesicles Antleron convEyXO

Wonder where Antleron innovations take shape?  Antleron's total R&D space has steadily expanded into an integrated lab that now spans over 500 square meters. That is about the size of a basketball court. The well-equipped labs enable our team to conduct R&D and pilot activities to develop bespoke custom bioprocesses. Antleron targets a wide range of life science applications, with a focus on advanced and personalized therapies. The specialists, methodologies, technologies are there to evolve from custom solution proof-of-concept to scalable production. Discover more through the link in comments. #bioprocess #bioprocesslabs #simulations #hybridmodels #cellculture #celltherapies #genetherapies #microfluidics #fluiddynamics #gmp #bioreactor #diagnostics #biomanufacturing Antleron 

How do you translate innovative molecular diagnostics to your specific point-of-care application? Antleron specialists create unique fluid pathway architectures for point-of-care diagnostics, bringing next-generation solutions closer to physicians and patients. These pathways integrate various unit operations, such as mixing and pinning, based on the requirements of the diagnostics company. Our proprietary 3D printing approach, utilizing a range of materials, enables rapid prototyping and offers significant design flexibility. Fully automated 3D printing reduces the complexity associated with the production of microfluidic cartridges for point-of-care devices. To successfully tackle custom diagnostics projects, we have developed a unique innovation toolbox—a risk-based, iterative framework: 1.    Identify the most influential parameters 2.    Model and simulate microfluidic devices 3.    Conduct preliminary in silico tests 4.    Create, test and optimize cartridges using 3D printing 5.    Feed experiment data into simulations and iterate efficiently until an optimal design is identified and can be produced. Ready to discuss your microfluidic cartridge project? Let's talk about your specific challenges and how we can collaborate to innovate your point-of-care application. #diagnostics #bioprinting #bioprocesses #3dprinting #additivemanufacturing #biomanufacturing #pointofcare #innovation

Today’s Fellow Friday story is dedicated to Pascale BERTHET. She is a highly experienced business development executive whose philosophy is to participate in the success of a therapeutic product that will change the lives of patients.    Pascale Berthet: “Antleron fuels my strong curiosity-based mindset when it comes to novel technologies and the creative fellows behind them. Together we focus on harnessing Antleron's multidisciplinary expertise in cell and gene therapies, coupled with exceptional engineering prowess, to develop the most robust commercial offerings with a long-term business outlook.”    Read and watch the entire article: https://lnkd.in/ej5Fwhy6 #bioprocess #celltherapy #genetherapy #scalable #sustainable #biomanufacturing #cellculture #bioprocessing #biotechnology #bioengineering #medicine #healthcare #ehealth #businessdevelopment #personalizedmedicine #companyculture #happyfellows Antleron

Factories of the future for cell and gene therapies – a far dream or close reality? Many existing and emerging technologies are currently available to cell & gene therapy developers globally. From sensors to end-to-end bioreactor platforms, the future is already at our doorstep. Yet, the field cannot shake the manufacturing bottleneck issue. Many processes are still operator dependent and therefore not scalable or economically viable. More broadly, shifting dynamics in CDMO availability, ever-growing clinical pipeline of life-saving treatments, risk aversion… varied factors contribute to the precarious situation. In our latest blogpost based on Antleron CEO Jan Schrooten’s lecture at the ATMP Supply Chain Conference, we explore the bioprocessing landscape and how close we are to scalable and sustainable cell & gene therapy manufacturing. Spoiler alert… not so far! Read here -> https://lnkd.in/eZij4uHQ What do you think? Are factories of the future a reality? At Antleron we develop innovative, custom bioprocess solutions with biology at the core. Reach out to have a conversation on how we could support your bioprocess development! #bioprocessing #industry40 #cellandgenetherapy #digitaltwin #innovation #pat #qualitybydesign #bioreactor

Our partners at Novasign will be attending the 28th ESACT Meeting in Edinburgh. Don't miss CEO Mark Duerkop's workshop on Sunday, 23rd, from 11:00-12:30, focusing on automation, AI, and CFD in bioprocess development. Titled "From Lab to Industry: Enabling Quality Control through Automation, AI, and Computational Fluid Dynamics," the workshop will explore how streamlined data acquisition and digital tools can accelerate bioprocess development. In collaboration with Novasign, we have pioneered a digital twin approach for scalable cell & gene therapy bioprocess development. This innovative approach bridges the gap from lab to patient by leveraging data across various scales and development stages. Combining process economics with biological insights, the digital twin eases the transition from a lab protocol to a manufacturing process. Join the workshop to gain valuable insights into the development of this innovative method. We wish all participants an insightful session and conference and are happy to take any questions – digitally!   Mark Duerkop Novasign ESACT - European Society for Animal Cell Technology   #bioprocessdevelopment #cellandgenetherap #automation #digitaltwin #simulation #processmodeling #artificialintelligence